– Highly efficient cell culture technology by adjusting the cell size and culture environment
– Technology for the ‘SMUP-Cell‘ proves the superiority of next generation stem cell culture technology.

MEDIPOST announced on June 27 that it has obtained patents in six European countries including UK, Germany, France, Italy, Switzerland and Spain on the method of culturing mesenchymal stem cells according to the cell size.

The name of this patent is the ‘Method For Culturing Mesenchymal Stem Cells According to the Cell Size’, which is the technology for the method of culturing mesenchymal stem cells with high efficiency by controlling the stem cell size and culture environment.

MEDIPOST envisages to apply this patent with the new process of the mesenchymal stem cell production, enabling the mass production of cells with good stem cell functions such as proliferation and differentiation.

Additionally, MEDIPOST has already obtained the patents of similar technologies in Korea, Japan, and Australia, and the next-generation stem cells to which the patented technology is applied are called the ‘SMUP-Cell‘ and are currently in trial production.

The MEDIPOST representative said that “this patent has already proven to be an international advantage in the technology of next-generation stem cell culture,” and that “pre-clinical studies are currently evaluating the efficacy and safety of new therapeutics using this technology.”